Cholesterol embolization syndrome (CES) is a multi-systemic disease caused by embolization of atherosclerotic plaque contents from proximal large-caliber artery to distal small to medium arteries, occurring spontaneously or more commonly after vascular intervention. This report is a comprehensive review of the reported cases of CES found in our literature search. We discuss the risk factors, clinical manifestations, management, and prognosis of CES. The major predisposing factors for CES include older age, male sex, atherosclerotic cardiovascular risk factors, anticoagulation, and femoral access route. The composite incidence of atheroembolic renal disease was 92% and mortality 63%. Our review highlights the importance to recognize this disease entity for the cardiologist and nephrologist. The embolization can affect the kidneys, skin, gastrointestinal system, and brain. Atheroembolic renal disease (AERD), also called as renal CES, is a part of this multi-systemic disease that may occur spontaneously, or after vascular trauma with angiographic catheters, vascular surgery, or the use of anticoagulants and thrombolytic agents. 
| INTRODUCTION
Cholesterol embolization syndrome (CES) refers to embolization of atherosclerotic plaque contents, primarily cholesterol crystals from a proximal large-caliber artery to distal small to medium arteries causing end-organ damage by mechanical plugging and inflammatory response. 1 The embolization can affect the kidneys, skin, gastrointestinal system, and brain. Atheroembolic renal disease (AERD), also called as renal CES, is a part of this multi-systemic disease that may occur spontaneously, or after vascular trauma with angiographic catheters, vascular surgery, or the use of anticoagulants and thrombolytic agents. 2 
First described by Danish physician Fenger and reported by
Danish pathophysiologist Peter Ludvig Panum in 1862 as an autopsy finding, 3 cholesterol embolization has been increasingly reported as a major cause of morbidity and mortality after vascular interventions. In a prospective study of 1786 patients who underwent left heart catheterization in Japan, CES was found in 25 patients (incidence of 1.4%). 4 In the spectrum of kidney injury patterns after cardiovascular intervention, AERD still remains under recognized. Patients with multisystem CES have been shown to have poor prognoses, with mortality varying from 58% to 90% 5 and debilitating morbidities like amputation of a limb or long term dependence on renal replacement therapy. It is therefore crucial to recognize it early as a complication post vascular interventions and also ensure appropriate preventive strategies are emphasized pre-procedure. This review summarizes the risk factors and epidemiology, clinical presentation, incidence of acute kidney injury (AKI) and management of CES.
studies, three prospective studies and two reviews. The review by Fine et al included patients from 1965 to 1985 using a MEDLINE literature search only. 6 Since then, further studies have been reported between the year 1978 and 2016 which have been included in this current review as an updated summary of the literature on atheroembolic disease.
Across 23 included studies, a total of 905 cases of CES have been reported, 648 of them were iatrogenic that is, after a vascular procedure. All the studies are summarized in Table 1 . 2, Among the retrospective studies included in this review, the incidence of CES varied from 2.9% (for endovascular stent graft for AAA repair) 11 to 25.5% for cardiac catheterizations and 30 % for aortograms. 27 
| Risk factors
Two of the 23 studies did not report the gender distribution of the population. 14, 27 Among the remaining total of 715 patients, 571
(79.8%) were men. The mean age of the population was 68. 9 years.
Four studies did not report the CAD risk factors of patients undergoing the procedures. 22, 23, 26, 27 Among the 19 studies that commented on CAD risk factors in patients with CES, 78% had hypertension, 18% had diabetes mellitus, 58% were smokers, 31% had hyperlipidemia, and 60% had known coronary artery disease. As highlighted by George et al, 28 male sex, age more than 50 years, and presence of risk factors for atherosclerosis are the major predisposing factors to develop atheroembolism after a vascular procedure.
Elevated levels of C-reactive protein (CRP) may be a considered a surrogate of enhanced immune or inflammatory activity of atherosclerotic lesions in patients with CES and has been shown to be an independent risk factor. In a prospective study by Fukumoto et al, 4 plasma CRP level in patients with CES was significantly higher than in patients without it (0.7 vs 2.4 mg/dL). Anticoagulation has been shown to be another risk factor. A total of 9/23 studies mentioned the use of warfarin, heparin, urokinase, or other fibrinolytic agents, which might have been associated with development of CES.The mechanism is believed to be due to intraplaque micro hemorrhage from ongoing anticoagulation leading to destabilization of atheroma in a patient with heavy atheromatous burden. 29 Previous studies have shown a temporal relationship of CES with thrombolytic and anticoagulation therapy even in the absence of vascular intervention, 30 thereby making it diagnostically challenging. The pathophysiology for the development of CES has been summarized in Figure 1 . 
| Type of procedure
Majority (67%) of the iatrogenic CES were after left heart catheterization with or without intervention. Sixteen percent were after a cardiovascular surgical procedure including coronary artery bypass graft (CABG), carotid endarterectomy, mitral valve replacement, aortoiliac, and aorto-femoral bypass graft. One study reported CES after TAVR. 15 The types of procedure leading to CES have been pictorially depicted in Figure 2 . Three prospective studies indicated toward a higher rate of CES with femoral catheterization. Fukumoto et al divided the population into two arms: disease and control, and showed that femoral approach was present in 80% of disease and 70% in control arm. 20 In a study by Scolari et al, femoral approach of catheterization was present in 78% of patients with CES (83 iatrogenic cases). 24 And in another prospective study by the same author (271 iatrogenic cases), femoral approach was reported to be more common. Given the robust data generated with AKI-MATRIX, it is reasonable to use the radial approach when feasible and with sufficient operator experience to reduce the burden of AKI, including atheroembolic disease post cardiac catheterization. AKI, acute kidney injury; NA, not available; LHC, left heart catheterization; AAA, abdominal aortic aneurysm; HTN, hypertension; DM, diabetes mellitus; HLD, hyperlipidemia; CAD, coronary artery disease; MI, myocardial infarction. | 413 atheromatous plaques of aorta and major arteries. The presence of AKI or renal involvement on biopsy was mentioned in all but one study. 27 Among these 22 studies, the composite incidence of AERD was 92.2%
| Clinical manifestations and diagnosis
(532/577). The timing of renal injury varied from 1 day to 3 months. In a review of Scolari et al, 20-30% patients with CES had pronounced renal impairment with acute onset, arising within 1 week, and dialysis was needed in 28-61% of patients with acute or subacute disease.
2,24
The outcomes of AERD in our review varied from complete recovery to dependence of chronic renal replacement therapy and mortality. A thorough evaluation should be done in all patients after a vascular procedure for development of AKI in acute and subacute setting.
| Management and prognosis
Till date, there are no definite guidelines on treatment of CES. Medical therapy that has been tried in CES included aspirin, steroids, statins, anti-platelet agents such as dipyridamole, vasodilators such as iloprost, hemostatic drugs including vitamin K, tranexamic acid, reptilase, and cyclophosphamide. Many patients received supportive care, and almost 50% needed renal replacement therapy. 14 In multiple case reports that were included, patients with CES were treated with statins. In addition to having lipid lowering effect, statins also possess anti-inflammatory properties. They exert anti-inflammatory effects on vascular wall through a variety of molecular pathways of innate and adaptive immune systems. 35 Statins have been shown to reduce the circulating levels of pro-inflammatory cytokines, and their effect on adhesion molecules. 35 At this time, there is limited robust data available on definitive therapies in the management of CES.
There was a wide heterogeneity noted in the follow-up period of different studies in reporting mortality. It varied from mortality reported within 3 days to a follow up period of 61.5 months. The composite mortality of patients with CES was 62.8% (407/648).
Multiple cases reported patients undergoing amputation, bowel resection for bowel infarction, and chronic hemodialysis or peritoneal dialysis therapy. 8 As highlighted before, the patients diagnosed with CES usually have advanced age and multiple CAD risk factors and comorbidities, which might be contributing to the high mortality rate in this patient population. With such high morbidity and mortality, it is important for clinicians to recognize CES and AERD as a complication of vascular interventions for its prompt recognition and management.
| SUMMARY AND FUTURE PROSPECTS
Cholesterol embolization syndrome is being increasingly recognized after vascular interventions, though it still continues to be one of the less explored field in cardio-nephrology research. This report is a comprehensive review of the reported cases of CES, risk factors, clinical manifestations, management, and prognosis of CES found in our English literature search. The major predisposing factors for CES include older age, male sex, atherosclerotic cardiovascular risk factors, anticoagulation, and femoral access route. It is important for the cardiologist and nephrologist to recognize the risk factors and presentation of this disease entity, to be able to risk stratify and prognosticate accordingly. Prospective larger trials are necessary to define therapeutic strategies that may modify the course of atheroembolic disease to reduce its mortality and morbidity burden.
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